MA43686A - Formulation liquide stable de gonadotrophines - Google Patents
Formulation liquide stable de gonadotrophinesInfo
- Publication number
- MA43686A MA43686A MA43686A MA43686A MA43686A MA 43686 A MA43686 A MA 43686A MA 43686 A MA43686 A MA 43686A MA 43686 A MA43686 A MA 43686A MA 43686 A MA43686 A MA 43686A
- Authority
- MA
- Morocco
- Prior art keywords
- gonadotrophins
- liquid formulation
- stable liquid
- stabilization
- formulation
- Prior art date
Links
- 239000012669 liquid formulation Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 102000006771 Gonadotropins Human genes 0.000 abstract 2
- 108010086677 Gonadotropins Proteins 0.000 abstract 2
- 239000002622 gonadotropin Substances 0.000 abstract 2
- 230000006641 stabilisation Effects 0.000 abstract 2
- 238000011105 stabilization Methods 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne en général le domaine de la stabilisation des formulations de gonadotrophines, en particulier les formulations liquides de gonadotrophines. La stabilisation est obtenue par une combinaison spécifique d'excipients, de préférence l'arginine et la méthionine. Dans un mode de réalisation préféré, la formulation ne comprend pas de tampon.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1603280.7A GB201603280D0 (en) | 2016-02-24 | 2016-02-24 | Stable liquid gonadotropin formulation |
| PCT/EP2017/054325 WO2017144659A1 (fr) | 2016-02-24 | 2017-02-24 | Formulation liquide stable de gonadotrophines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA43686A true MA43686A (fr) | 2019-01-02 |
| MA43686B1 MA43686B1 (fr) | 2021-03-31 |
Family
ID=55806922
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA43686A MA43686B1 (fr) | 2016-02-24 | 2017-02-24 | Formulation liquide stable de gonadotrophines |
| MA52595A MA52595B1 (fr) | 2016-02-24 | 2017-02-24 | Formulation liquide stable de gonadotrophines |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA52595A MA52595B1 (fr) | 2016-02-24 | 2017-02-24 | Formulation liquide stable de gonadotrophines |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US10792334B2 (fr) |
| EP (3) | EP4257149A3 (fr) |
| JP (3) | JP6932710B2 (fr) |
| KR (1) | KR102756413B1 (fr) |
| CN (2) | CN113398250B (fr) |
| AR (1) | AR107782A1 (fr) |
| AU (2) | AU2017222292B2 (fr) |
| BR (1) | BR112018015166A2 (fr) |
| CA (1) | CA3012759A1 (fr) |
| CL (1) | CL2018001984A1 (fr) |
| CO (1) | CO2018007810A2 (fr) |
| DK (2) | DK3791860T5 (fr) |
| EA (1) | EA036383B1 (fr) |
| ES (2) | ES2862193T3 (fr) |
| FI (1) | FI3791860T3 (fr) |
| GB (1) | GB201603280D0 (fr) |
| HR (2) | HRP20210367T1 (fr) |
| HU (2) | HUE064432T2 (fr) |
| IL (1) | IL260626B2 (fr) |
| JO (1) | JOP20170046B1 (fr) |
| LT (2) | LT3419595T (fr) |
| MA (2) | MA43686B1 (fr) |
| MD (2) | MD3419595T2 (fr) |
| MX (1) | MX381709B (fr) |
| MY (1) | MY193138A (fr) |
| PH (1) | PH12018501688B1 (fr) |
| PL (2) | PL3419595T3 (fr) |
| PT (2) | PT3791860T (fr) |
| RS (2) | RS61604B1 (fr) |
| SG (1) | SG11201806140SA (fr) |
| SI (2) | SI3791860T1 (fr) |
| TN (1) | TN2018000284A1 (fr) |
| TW (1) | TWI755377B (fr) |
| UA (1) | UA123107C2 (fr) |
| WO (1) | WO2017144659A1 (fr) |
| ZA (1) | ZA201804944B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201603280D0 (en) | 2016-02-24 | 2016-04-13 | Ferring Bv | Stable liquid gonadotropin formulation |
| US20190262314A1 (en) * | 2018-02-26 | 2019-08-29 | Slayback Pharma Llc | Ready-to-use dexmedetomidine compositions |
| WO2020071912A1 (fr) * | 2018-10-02 | 2020-04-09 | Innocore Technologies B.V. | Formulations à libération prolongée de gonadotrophine chorionique humaine (hcg) |
| CN114404575A (zh) * | 2020-12-07 | 2022-04-29 | 苏州智核生物医药科技有限公司 | 一种重组人促甲状腺素注射液 |
| WO2022197963A1 (fr) * | 2021-03-19 | 2022-09-22 | Pfizer Inc. | Compositions d'hormone de croissance à action prolongée |
| CN118209739A (zh) * | 2024-03-19 | 2024-06-18 | 厦门宝太和瑞生物技术有限公司 | 促黄体生成素检测试剂盒 |
| KR102821987B1 (ko) * | 2024-10-24 | 2025-06-26 | 에이디텍 주식회사 | 베타 코어 단편 hCG를 유효성분으로 포함하는 난임 치료용 조성물 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0803832A3 (fr) | 1996-02-28 | 2000-05-31 | Hitachi, Ltd. | Dispositif d'affichage de solde du type étui à carte |
| IL122732A0 (en) * | 1997-01-15 | 1998-08-16 | Akzo Nobel Nv | Liquid gonadotropin-containing formulation its preparation and a device containing same |
| IL140984A0 (en) * | 1998-07-23 | 2002-02-10 | Lilly Co Eli | Fsh and fsh variant formulations, products and methods |
| BRPI0611901A2 (pt) | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
| KR101105871B1 (ko) * | 2005-09-27 | 2012-01-16 | 주식회사 엘지생명과학 | 인 난포자극호르몬의 안정한 용액 제형 |
| GB0700523D0 (en) | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| BRPI0818324B8 (pt) | 2007-11-01 | 2021-05-25 | Merck Serono Sa | formulação líquida contendo hormônio luteinizante (lh) ou uma variante do mesmo, seu uso, sua forma de apresentação, processo para a sua preparação e composição farmacêutica |
| US8420081B2 (en) | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| NZ586588A (en) | 2008-02-08 | 2012-10-26 | Biogenerix Ag | Formulation of ( follice stimulating hormone) fsh and varients with benzalkonium chloride and benzyl alcohol |
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| KR101668502B1 (ko) | 2008-11-04 | 2016-10-21 | 아스카 세이야쿠 가부시키가이샤 | 난포자극호르몬 함유 수성 조성물 |
| RU2553375C2 (ru) * | 2010-02-12 | 2015-06-10 | Интас Биофармасьютикалс Лимитед | Жидкий состав фолликулостимулирующего гормона |
| WO2011108010A2 (fr) | 2010-03-05 | 2011-09-09 | Intas Biopharmaceuticals Limited | Préparation liquide thermostable de gonadotropines |
| EP2417982A1 (fr) * | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilisation de gonadotrophines |
| AP2016009159A0 (en) * | 2013-11-12 | 2016-04-30 | Cadila Healthcare Ltd | Formulation for gonadotropins |
| GB201603280D0 (en) * | 2016-02-24 | 2016-04-13 | Ferring Bv | Stable liquid gonadotropin formulation |
-
2016
- 2016-02-24 GB GBGB1603280.7A patent/GB201603280D0/en not_active Ceased
-
2017
- 2017-02-19 JO JOP/2017/0046A patent/JOP20170046B1/ar active
- 2017-02-23 TW TW106106132A patent/TWI755377B/zh active
- 2017-02-24 SI SI201731448T patent/SI3791860T1/sl unknown
- 2017-02-24 PH PH1/2018/501688A patent/PH12018501688B1/en unknown
- 2017-02-24 CA CA3012759A patent/CA3012759A1/fr active Pending
- 2017-02-24 EP EP23194814.2A patent/EP4257149A3/fr not_active Withdrawn
- 2017-02-24 JP JP2018544561A patent/JP6932710B2/ja active Active
- 2017-02-24 ES ES17707527T patent/ES2862193T3/es active Active
- 2017-02-24 MA MA43686A patent/MA43686B1/fr unknown
- 2017-02-24 SG SG11201806140SA patent/SG11201806140SA/en unknown
- 2017-02-24 DK DK20202758.7T patent/DK3791860T5/da active
- 2017-02-24 EA EA201891905A patent/EA036383B1/ru not_active IP Right Cessation
- 2017-02-24 MY MYPI2018001301A patent/MY193138A/en unknown
- 2017-02-24 PT PT202027587T patent/PT3791860T/pt unknown
- 2017-02-24 PT PT177075272T patent/PT3419595T/pt unknown
- 2017-02-24 KR KR1020187027128A patent/KR102756413B1/ko active Active
- 2017-02-24 HU HUE20202758A patent/HUE064432T2/hu unknown
- 2017-02-24 HR HRP20210367TT patent/HRP20210367T1/hr unknown
- 2017-02-24 AR ARP170100475A patent/AR107782A1/es not_active Application Discontinuation
- 2017-02-24 RS RS20210361A patent/RS61604B1/sr unknown
- 2017-02-24 DK DK17707527.2T patent/DK3419595T3/da active
- 2017-02-24 WO PCT/EP2017/054325 patent/WO2017144659A1/fr not_active Ceased
- 2017-02-24 BR BR112018015166A patent/BR112018015166A2/pt active Search and Examination
- 2017-02-24 MA MA52595A patent/MA52595B1/fr unknown
- 2017-02-24 SI SI201730666T patent/SI3419595T1/sl unknown
- 2017-02-24 UA UAA201809497A patent/UA123107C2/uk unknown
- 2017-02-24 ES ES20202758T patent/ES2966262T3/es active Active
- 2017-02-24 LT LTEP17707527.2T patent/LT3419595T/lt unknown
- 2017-02-24 RS RS20231172A patent/RS64929B1/sr unknown
- 2017-02-24 MD MDE20190039T patent/MD3419595T2/ro unknown
- 2017-02-24 MX MX2018010201A patent/MX381709B/es unknown
- 2017-02-24 CN CN202110585922.3A patent/CN113398250B/zh active Active
- 2017-02-24 TN TNP/2018/000284A patent/TN2018000284A1/en unknown
- 2017-02-24 AU AU2017222292A patent/AU2017222292B2/en active Active
- 2017-02-24 PL PL17707527T patent/PL3419595T3/pl unknown
- 2017-02-24 EP EP20202758.7A patent/EP3791860B1/fr active Active
- 2017-02-24 PL PL20202758.7T patent/PL3791860T3/pl unknown
- 2017-02-24 US US16/079,428 patent/US10792334B2/en active Active
- 2017-02-24 EP EP17707527.2A patent/EP3419595B1/fr active Active
- 2017-02-24 MD MDE20210250T patent/MD3791860T2/ro unknown
- 2017-02-24 FI FIEP20202758.7T patent/FI3791860T3/fi active
- 2017-02-24 LT LTEP20202758.7T patent/LT3791860T/lt unknown
- 2017-02-24 HU HUE17707527A patent/HUE053492T2/hu unknown
- 2017-02-24 HR HRP20231477TT patent/HRP20231477T1/hr unknown
- 2017-02-24 CN CN201780013134.9A patent/CN108883061B/zh active Active
-
2018
- 2018-07-17 IL IL260626A patent/IL260626B2/en unknown
- 2018-07-23 CL CL2018001984A patent/CL2018001984A1/es unknown
- 2018-07-23 ZA ZA2018/04944A patent/ZA201804944B/en unknown
- 2018-07-27 CO CONC2018/0007810A patent/CO2018007810A2/es unknown
-
2020
- 2020-09-14 US US17/020,279 patent/US11666635B2/en active Active
-
2021
- 2021-08-18 JP JP2021133422A patent/JP2021191760A/ja active Pending
-
2022
- 2022-01-05 AU AU2022200027A patent/AU2022200027A1/en not_active Abandoned
-
2023
- 2023-04-21 US US18/138,000 patent/US12447196B2/en active Active
- 2023-09-15 JP JP2023150308A patent/JP2023164573A/ja active Pending
-
2025
- 2025-04-02 US US19/098,420 patent/US20250352621A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43686A (fr) | Formulation liquide stable de gonadotrophines | |
| AR122746A2 (es) | Una formulación farmacéutica líquida estable de anticuerpo | |
| EA201790989A1 (ru) | Стабильный препарат раствора белка, содержащего анти-vegf антитело в высокой концентрации | |
| CY1122181T1 (el) | Φαρμακοτεχνικη μορφη αντισωματος | |
| TR200801336T1 (tr) | Kararlılığı artmış zayıf su çöznurluğune sahip ilaçların preparasyonuna yönelik kompozisyonlar ve yöntemler. | |
| CR20180554A (es) | Preparaciones que contienen anticuerpos | |
| AR111455A1 (es) | Formulación estable de anticuerpo | |
| CL2020002252A1 (es) | Formulación oftálmica. | |
| CL2019002190A1 (es) | Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984) | |
| EA201490801A1 (ru) | Композиции этанерцепта, стабилизированные комбинациями сахаров и полиолов | |
| CU20190015A7 (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden | |
| PE20170948A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r) | |
| WO2014066468A8 (fr) | Formulation d'anticorps, stable, à faible viscosité | |
| MX2021002935A (es) | Formulacion de anticuerpos contra csf-1r. | |
| EA201991798A1 (ru) | Стабильные при хранении составы | |
| EA202091398A1 (ru) | Составы вакцинных композиций от вируса денге | |
| MX2021007393A (es) | Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf. | |
| EA202092926A2 (ru) | Лиофилизированные составы, содержащие фактор ix | |
| UY38153A (es) | Formulaciones acuosas estables de anticuerpos anti-tau | |
| CL2024003444A1 (es) | Formulación farmacéutica líquida estable que comprende un anticuerpo biespecífico anti-cd20/cd3 humano. | |
| AR122427A1 (es) | Excipientes poliméricos para formulaciones biofarmacéuticas | |
| EA201800226A1 (ru) | Фармацевтическая композиция, обладающая анксиолитическим и снотворным действием | |
| CO2019010902A1 (es) | Composición farmacéutica líquida que contiene dantrolene sódico | |
| UA123395U (uk) | Фармацевтична композиція ністатину у формі оральної суспензії |